我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1989
273 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1796
终止
52
2.6%
招募中
374
18.8%
暂停
1
0.1%
撤回
40
2.0%
进行中（未招募）
152
7.6%
Unknown
249
12.5%
已完成
1000
50.3%
Enrolling By Invitation
尚未招募
120
6.0%
暂无批准数据
- Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening. - A recently published study demonstrated that Nu.Q® Cancer test can accurately detect 21 different cancer types with high specificity, positioning it as a potential standalone pan-cancer test or complement to existing liquid biopsy technologies. - The company is pursuing multiple licensing agreements with diagnostic and liquid biopsy companies in 2025, targeting the $20 billion liquid biopsy market with a test that can run on existing automated platforms worldwide.
